DekaBank Deutsche Girozentrale
BDTX icon

DekaBank Deutsche Girozentrale’s Black Diamond Therapeutics BDTX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,400
Closed -$152K – 1378
2021
Q2 		$152K Hold
12,400
– – ﹤0.01% 1274
2021
Q1 		$280K Hold
12,400
– – ﹤0.01% 1128
2020
Q4 		$409K Buy
+12,400
New +$407K ﹤0.01% 1057

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

DekaBank Deutsche Girozentrale's BDTX Position: Q3 2021 in Review

DekaBank Deutsche Girozentrale sold out of Black Diamond Therapeutics (BDTX) in Q3 2021, closing a stake of 12,400 shares — an estimated $152K sold.

DekaBank Deutsche Girozentrale first reported a position in BDTX in Q4 2020 and held it in 3 quarters. The position peaked at $409K in Q4 2020. 101 funds tracked by Wall St. Rank hold BDTX as of Q3 2021.

  • DekaBank Deutsche Girozentrale reported no remaining Black Diamond Therapeutics position as of Q3 2021 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 12,400 Black Diamond Therapeutics shares in Q3 2021, an estimated $152K.
  • DekaBank Deutsche Girozentrale first reported a position in Black Diamond Therapeutics in Q4 2020 and held it in 3 quarters.
  • DekaBank Deutsche Girozentrale's Black Diamond Therapeutics position peaked at $409K in Q4 2020.
  • 101 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q3 2021, filed 22 Oct 2021.